Saturday 17 October 2026 Export CELZ’s income statement to Excel — free account

Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6,000.00, down 45.5% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 14.6% and free cash flow fell 27.1%, each against the same quarter a year earlier.

0.74 0.08 −9.76%

Follow CELZ

Alert me

Market cap: $5.4M
P/E: 0.0×
Fwd P/E: −1.3×
Dividend yield: —
F-score: 4/9
Altman Z: −4.32
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 5.39

Revenue 0.02

Net Income (6.04)

Free Cash Flow (5.90)

Net Debt (8.84)

Current Ratio 12.91

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.31)

P/S ratio 161.13

P/B ratio 0.32

Past 5Y EPS Growth —

This Y EPS Growth 53.17%

Next Y EPS Growth 25.42%

Next Y revenue growth 1,001,233.33%

Next 5Y EPS Growth 30.39%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 47.45%

10-year low 10-year high

P/B against its own 10 years 11.72%

10-year low 10-year high

EV/FCF against its own 10 years 73.14%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	10	6	7	9
Receivables	—	—	—	—
Inventory	0	0	—	—
Other	—	—	—	—
	10	6	7	9

	2023	2024	2025	Q'26
Payables	0	0	0	1
ST’ Debt	—	—	—	—
Other	0	0	0	0
	0	0	0	1

Compound Annual Growth %

	10y	5y	3y
Sales	—	(48.43%)	(59.24%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	65.27%	0.00%	(22.01%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	0	—	—	0	0
’24	—	0	—	0	0
’23	—	—	0	0	0
’22	0	—	0	0	0
’21	—	0	0	0	0
’20	0	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(2)	(1)	(1)	(2)	(6)
’24	(1)	(1)	(1)	(2)	(5)
’23	(4)	(1)	(1)	(2)	(8)
’22	(2)	(2)	(1)	(4)	(8)
’21	0	0	0	(1)	(2)
’20	0	0	0	0	0

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(2)	(1)	(1)	(2)	(6)
’24	(1)	(1)	(1)	(2)	(6)
’23	(4)	(1)	(1)	(2)	(8)
’22	(2)	(2)	(6)	(4)	(8)
’21	0	0	0	(1)	(2)
’20	0	0	0	0	(1)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.38)	(0.41)	—	—	—
’25	(0.83)	(0.48)	(0.48)	(0.80)	(2.52)
’24	(0.73)	(1.11)	(0.75)	(1.12)	(3.71)
’23	(0.70)	(0.78)	(1.02)	(1.21)	(3.76)
’22	(1.79)	(1.99)	(0.70)	(5.30)	(9.30)
’21	111.84	(12.52)	(7.52)	(32.66)	59.13
’20	0.05	(0.11)	1.45	(628.77)	(627.38)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	8,250.00	7,500.00	1,575.00	75.00	6.50	15.83	3.30	3.60	1.96	1.50	Analyst estimates 2026–2028 Powerpack
	High	487,500.00	525,000.00	52,500.00	11,625.00	525.00	650.00	51.45	14.20	10.28	6.90
People
People	Employees	—	—	—	—	—	5	4	5	4	4
	Revenue/emp, $m	—	0.00	0.00	0.00	0.00	0.02	0.02	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	0	0	0	0	0	0	0	0	0
	Gross margin, %	0.00	(66.67)	43.41	72.51	69.24	45.33	67.83	60.00	60.00	63.33
	EBT	(1)	(3)	(14)	(8)	(36)	19	(10)	(5)	(5)	(6)
	EBT margin, %	0.00	(55,397.92)	(10,977.25)	(5,126.10)	(22,082.19)	21,881.32	(11,449.21)	(58,740.00)	(49,940.91)	(99,916.67)
	Net income	(1)	(3)	(14)	(8)	(36)	19	(10)	(5)	(5)	(6)
	Depreciation	0	0	1	2	1	4	0	0	0	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.32	0.16	2.84	0.34	0.08	0.01	0.01	0.00
	Earnings	(0.08)	(0.25)	(34.96)	(8.20)	(627.38)	73.75	(9.30)	(3.76)	(3.71)	(2.52)
	Cash flow	(0.05)	(0.08)	(2.69)	(1.17)	(7.51)	(8.51)	(7.13)	(5.70)	(3.58)	(2.46)
	Capex	0.00	0.00	0.00	0.00	(4.32)	0.00	0.00	(0.07)	(0.14)	0.00
	Free cash flow	(0.05)	(0.08)	(2.69)	(1.17)	(11.82)	(8.51)	(7.13)	(5.77)	(3.72)	(2.46)
	Book value	(0.02)	(0.21)	(10.23)	(7.80)	(687.44)	39.22	14.51	7.35	4.28	3.16
	Shares, m	9	11	0	1	0	0	1	1	1	2
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	0.30	0.00	0.00	0.00	0.00
	P/S	—	0.00	23,313.55	1,406.15	48.92	54.67	26.00	78.39	170.99	274.72
	P/B	—	0.00	0.00	0.00	0.00	0.56	0.26	0.63	0.54	0.62
	EV/Sales	—	0.00	23,316.59	1,412.04	53.13	(46.05)	(26.44)	(41.09)	(120.12)	(142.33)
	EV/FCF	—	(107,567.26)	(2,756.42)	(192.64)	(11.00)	1.88	0.31	0.25	0.23	0.22
Cash, $m
Cash, $m	Operating cash flow	0	(1)	(1)	(1)	0	(2)	(8)	(8)	(5)	(6)
	Capex	0	—	—	—	0	—	—	0	0	—
	Free cash flow	0	(1)	(1)	(1)	(1)	(2)	(8)	(8)	(6)	(6)
Balance, $m
Balance, $m	Working capital	0	(2)	(4)	(9)	(40)	10	15	10	6	7
	Total debt	0	0	1	1	1	—	—	—	—	—
	Net debt	0	0	0	1	1	(11)	(8)	(10)	(6)	(7)
	Shareholders’ equity	0	(2)	(4)	(8)	(40)	10	16	10	6	8
Returns, %
Returns, %	ROA	(411.77)	(1,011.83)	(4,014.61)	(1,683.27)	(5,818.55)	320.57	(66.62)	(35.36)	(63.20)	(82.81)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	(84.87)	(984.74)	(895.02)	(1,213.03)
	ROE	1,414.77	222.15	438.12	140.55	151.73	(129.86)	(77.78)	(40.34)	(65.85)	(86.53)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NRSN NeuroSense Therapeutics Ltd.	$6.0M	— (loss-making)	—	—	n/m	−23,458.82% (below 0%: shrinking)	—	0.00%	Compare
IMNN Imunon, Inc.	$6.0M	— (loss-making)	— (loss-making)	0.00%	n/m	−4.24% (below 0%: shrinking)	0.00%	0.00%	Compare
ORGS Orgenesis Inc.	$5.7M	— (loss-making)	1.0×	+82.42% (above 0%: growing)	n/m	−317.93% (below 0%: shrinking)	2,780.73%	(6,044.52%)	Compare
CANF Can-Fite Biopharma Ltd	$5.6M	— (loss-making)	— (loss-making)	−1.18% (below 0%: shrinking)	n/m	+12.63% (above 0%: growing)	0.00%	0.00%	Compare
BGMS Bio Green Med Solution, Inc.	$5.5M	— (loss-making)	— (loss-making)	+3,260.00% (above 0%: growing)	n/m	+66.67% (above 0%: growing)	23.51%	(124.40%)	Compare
CELZ Creative Medical Technology Holdings, Inc.	$5.4M	— (loss-making)	— (loss-making)	0.00%	n/m	−27.05% (below 0%: shrinking)	66.67%	0.00%
CDIO Cardio Diagnostics Holdings, Inc.	$5.2M	— (loss-making)	— (loss-making)	−28.00% (below 0%: shrinking)	n/m	+15.58% (above 0%: growing)	100.00%	(27,742.59%)	Compare
PULM Pulmatrix, Inc.	$5.2M	— (loss-making)	— (loss-making)	−99.86% (below 0%: shrinking)	n/m	+41.26% (above 0%: growing)	100.00%	0.00%	Compare
RVPH Reviva Pharmaceuticals Holdings, Inc.	$5.0M	— (loss-making)	—	—	n/m	+57.80% (above 0%: growing)	—	0.00%	Compare
Median of peers	$5.6M	—	—	−0.59%	—	+14.11%	61.76%	0.00%

All 614 Biotechnology stocks →

Creative Medical Technology Holdings, Inc. (CELZ) key facts

Concern: Creative Medical Technology Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6,000.00, down 45.5% from fiscal 2024.
Creative Medical Technology Holdings, Inc. (CELZ) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CELZ traded at $0.74, a market capitalization of $5.4 million.
Return on equity was −86.5% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −4.32 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.